Article
The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients.
Pharmacogenomics - 1 Sept 2011
de Jonge Hylke, Metalidis Christoph, Naesens Maarten, Lambrechts Diether, Kuypers Dirk R J
Abstract excerpt
AIM: Recently a SNP of the gene encoding P450 oxidoreductase (POR*28; rs1057868C>T) has been associated with increased in vivo CYP3A activity using midazolam as a drug probe. Because tacrolimus is metabolized by CYP3A isoenzymes, this SNP might affect tacrolimus pharmacokinetics. MATERIALS & METHODS: To test this hypothesis we performed a study in a cohort of 298 de novo renal allograft recipients stratified...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.